The multifunctional Ca 2+ /calmodulin-dependent kinase II (CaMKII) is activated by vasoconstrictors in vascular smooth muscle cells (VSMC), but its impact on vasoconstriction remains unknown. We hypothesized that CaMKII inhibition in VSMC decreases vasoconstriction. Using novel transgenic mice that express the inhibitor peptide CaMKIIN in smooth muscle (TG SM-CaMKIIN), we investigated the effect of CaMKII inhibition on L-type Ca 2+ channel current (I Ca ), cytoplasmic and sarcoplasmic reticulum Ca 2+ , and vasoconstriction in mesenteric arteries. In mesenteric VSMC, CaMKII inhibition significantly reduced action potential duration and the residual I Ca 50 ms after peak amplitude, indicative of loss of L-type Ca 2+ channel-dependent I Ca facilitation. Treatment with angiotensin II or phenylephrine increased the intracellular Ca 2+ concentration in wild-type but not TG SM-CaMKIIN VSMC. The difference in intracellular Ca 2+ concentration was abolished by pretreatment with nifedipine, an L-type Ca 2+ channel antagonist. In TG SM-CaMKIIN VSMC, the total sarcoplasmic reticulum Ca 2+ content was reduced as a result of diminished sarcoplasmic reticulum Ca 2+ ATPase activity via impaired derepression of the sarcoplasmic reticulum Ca 2+ ATPase inhibitor phospholamban. Despite the differences in intracellular Ca 2+ concentration, CaMKII inhibition did not alter myogenic tone or vasoconstriction of mesenteric arteries in response to KCl, angiotensin II, and phenylephrine. However, it increased myosin light chain kinase activity. These data suggest that CaMKII activity maintains intracellular calcium homeostasis but is not required for vasoconstriction of mesenteric arteries. (Hypertension. 2013;62:434-441.) • Online Data Supplement
V ascular smooth muscle cell (VSMC) contraction regulates the vasomotor tone and affects blood pressure. Vasoconstrictors, such as angiotensin II (Ang II) and vasopressin, increase VSMC intracellular Ca 2+ concentration [Ca 2+ ] i and thereby activate the multifunctional Ca 2+ /calmodulin-dependent kinase II (CaMKII). 1 CaMKII isoforms γ and δ are present in many cells, including VSMC. 2, 3 All CaMKII isoforms are activated by Ca 2+ -bound calmodulin. 4 Subsequent autophosphorylation at Thr286 then leads to sustained CaMKII activation even after [Ca 2+ ] i declines to baseline values. CaMKII has been implicated as a regulator of smooth muscle contraction for more than a decade, [5] [6] [7] [8] [9] but progress has been hampered by imperfect tools to specifically dissect its role in vascular reactivity.
Although it is well-established that CaMKII activity is increased in response to vasoconstrictors, the data in different smooth muscle-rich organs are conflicting as to whether CaMKII promotes 8, 9 or inhibits force development or maintenance. 7 Several CaMKII substrates, including myosin light chain kinase (MLCK) and myosin light chain (MLC) 20, 5, 6, [9] [10] [11] caldesmon, 12 and calponin, 13 have been identified using in vitro studies. Furthermore, CaMKII has been shown to activate L-type Ca 2+ channel (LTCC) current (I Ca ) in other excitable tissues. [14] [15] [16] [17] However, no direct evidence has linked CaMKII activation with these targets to regulate vasoconstriction. In the vascular system, the effect of CaMKII on vasoconstriction has only been studied in large-conductance blood vessels, 8, 9 which generally do not contribute to the regulation of peripheral vascular resistance or blood pressure. Furthermore, most experiments were performed using the pharmacological CaMKII inhibitor KN-93 that has CaMKIIindependent antagonist effects on LTCC and voltagedependent potassium channels. [18] [19] [20] To directly examine the contribution of activated CaMKII to vasoconstriction, we developed a novel transgenic mouse model in which the potent and specific endogenous CaMKII inhibitor (CaMKIIN) peptide is expressed in smooth muscle cells. CaMKIIN has a superior potency (IC 50 ≈50 nmol/L) and specificity (eg, no measurable activity against CAMKIV or protein kinase C) compared with other pharmacological and peptide CaMKII antagonists. It inhibits the activity of all CaMKII isoforms and splice variants. 21 We chose this approach over available CaMKII isoform-specific knockout models 22 because we previously reported compensatory upregulation of the remaining isoforms in CaMKIIδ −/− arteries. 22 We previously showed that a peptide inhibitor similar to CaMKIIN expressed specifically in the heart acted as a potent CaMKII inhibitor. This model has been instrumental in understanding CaMKII function in heart failure and arrhythmogenesis. 23 We hypothesized that CaMKII promotes VSMC contraction and agonist-mediated vasoconstriction by regulating intracellular Ca 2+ levels. In this study, we dissected the effect of CaMKII inhibition on known CaMKII substrates, measured [Ca 2+ ] i in response to agonists that regulate smooth muscle constriction, and integrated these data with vasoconstriction studies in mesenteric arteries.
Methods
Experiments were performed in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals and approved by the Institutional Animal Care and Use Committees. Mice carrying cDNA for the hemagglutinin (HA)-tagged CaMKIIN peptide downstream of a floxed enhanced green fluorescent protein gene followed by a stop codon were mated with animals carrying a Cre recombinase gene controlled by the smooth muscle protein 22-α (SM22α) promoter to generate TG SM-CaMKIIN mice. The littermate control group of animals carried SM22α-Cre only. VSMC were isolated from second-order mesenteric arteries for patch clamping or [Ca 2+ ] i measurements by Fura-2. Vasoconstriction and myogenic tone were determined in pressurized second-order mesenteric arteries using video microscopy. Values are expressed as mean±SEM and compared within groups using Student t test or ANOVA, followed by Bonferroni correction. A P<0.05 was considered significant. Additional experimental detail is provided in the online-only Data Supplement.
Results

Generation of Mice With CaMKII Inhibition Limited to VSMC
We investigated the role of CaMKII in vascular contractility using a novel transgenic model that expresses the potent and specific CaMKII inhibitor peptide CaMKIIN selectively in smooth muscle (TG SM-CaMKIIN; Figure S1A in the onlineonly Data Supplement). After interbreeding with smooth muscle-specific TG SM22α-cre mice, HA-tagged CaMKIIN was expressed in the aortic media ( Figure S1B ). Quantitative realtime polymerase chain reaction revealed high CaMKIIN transcript levels in the aorta in TG SM-CaMKIIN mice compared with other tissues ( Figure S1C ). We attribute the lower, but detectable transcript levels in skeletal muscle and heart to the presence of CaMKIIN in small arterial vessels in these tissues. Robust expression of CaMKIIN was also detected in other vascular beds ( Figure S1D ). Immunoblots for the HA-tag of CaMKIIN confirmed its presence in TG SM-CaMKIIN aortas, with minor expression in TG HA-tagged CaMKIIN peptide aortas ( Figure S1E ). CaMKII activity assays validated . Ca 2+ /calmodulin-dependent kinase II (CaMKII) inhibition reduces L-type Ca 2+ channel activity in vascular smooth muscle cell (VSMC). A, Representative examples of stimulated action potentials in wild type (WT) and TG SM-CaMKIIN VSMC. B, Action potential duration (APD) measured at 90% reduction in current from the upstroke (n=5 each). C and D, Current-density/voltage relationships for whole-cell I Ca recorded in VSMC from WT (n=7), TG SM-CaMKIIN (n=9) in 10 mmol/L BaCl 2 . Average data for peak I Ca density in response to a voltage command pulse to 0 mV. E and F, Residual I Ca 50 ms after peak amplitude (R50; n=10 for each genotype). G and H, I Ca at baseline (black) and after 5 repetitive depolarizations (red). Repetitive depolarizations were induced by depolarizing to +10 mV at −70 holding potential with 0.5 Hz (n=6 in WT, n=7 in TG SM-CaMKIIN). I, Summary data for relative peak I Ca in response to a train of 10 voltage command pulses. J, Relative peak current I Ca histogram of the fifth command pulse normalized to I Ca of the first command pulse. K, Representative phosphorylated (p-Cavβ3) and total β3 subunit (Cavβ3) and total Cav1.2α1c immunoblots from mesenteric artery lysates. Lysates from 5 to 7 mice were pooled per lane. L, Summary data for Cavβ3 phosphorylation, normalized to total Cavβ3, and for Cav1.2α1c, normalized to β-actin (n=3). *P<0.05 compared with WT. WT (black lines or bars) and TG SM-CaMKIIN (gray). functional CaMKII inhibition, with a significant 65% decrease in CaMKII activity in aortas of TG SM-CaMKIIN mice compared with wild-type (WT) mice ( Figure S1F ). We also evaluated the expression of CaMKII isoforms in mesenteric lysates and observed significantly increased transcript levels of CaMKIIγ and CaMKIIδ in TG SM-CaMKIIN mice ( Figure  S1G and S1H). Other baseline characteristics are provided in Figure S2 . The mean arterial blood pressure in spontaneously active mice was not different between genotypes.
LTCC Opening Is Decreased in VSMC From TG SM-CaMKIIN Mice
LTCC opening is the primary mediator of Ca 2+ influx in VSMC. 24 In myocardium, CaMKII phosphorylates the LTCC β-subunit 15 and drives the channel into an active gating mode with frequent, prolonged openings. 25 Therefore, we investigated whether CaMKII inhibition in VSMC inhibits LTCC function and decreases Ca 2+ influx. First, we determined the action potential duration in VSMC isolated from second-order mesenteric arteries. We detected significant shortening of the action potential duration by 35% in TG SM-CaMKIIN VSMC relative to WT VSMC ( Figure 1A and 1B).
Next, we assessed whether CaMKII inhibition decreases the membrane density of the LTCC. The current density was not significantly reduced in TG SM-CaMKIIN VSMC ( Figure 1C and 1D). We tested whether CaMKII inhibition affects the LTCC inactivation by measuring the residual I Ca 50 ms after peak amplitude (R 50 ). R 50 was significantly reduced in TG SM-CaMKIIN VSMC ( Figure 1E and 1F ). In addition, we determined the increase in peak LTCC current after repetitive depolarizations. This increase, also called I Ca facilitation, is known to be CaMKII-dependent. 25 In WT VSMC, we detected a 27% increase in peak current after 5 repetitive depolarizations. In contrast, facilitation was abolished in TG SM-CaMKIIN VSMC ( Figure 1G-1J ).
CaMKII has recently been reported to regulate the expression of the LTCC α1c subunit (Cav1.2). 26 We detected the expression of LTCC Cav1.2 and the β 3 -subunit (Cavβ3), the predominant Cavβ subunit in mesenteric arteries ( Figure 1K and 1L). CaMKII inhibition did not affect Cav1.2 or Cavβ3 subunit expression. CaMKII phosphorylates Cavβ subunits, including Cavβ3, and thereby increases the LTCC opening probability. 27 To verify that the phosphorylation of Cavβ3 was decreased under CaMKII inhibition, we performed immunoblots for phospho-β3 and observed a significant reduction in TG SM-CaMKIIN mesenteric arteries compared with WT ( Figure 2K and 2L; Figure S3 ). Together, these results suggest that CaMKII inhibition in VSMC reduces Cavβ3 subunit phosphorylation and channel opening.
CaMKII Inhibition in VSMC Reduces Ang II-Stimulated [Ca 2+ ] i
Ang II increases Ca 2+ influx through LTCC. 28 Given that LTCC inhibition reduced I Ca and shortened the action potential in VSMC, we hypothesized that TG SM-CaMKIIN VSMC have impaired Ca 2+ influx in response to Ang II. To test this hypothesis, freshly isolated mesenteric VSMC were treated with 100 nmol/L Ang II, and [Ca 2+ ] i was determined by Fura-2 fluorescence ratio imaging. Baseline [Ca 2+ ] i was similar between the genotypes (Figure 2A ). Ang II produced the anticipated increase in [Ca 2+ ] i in WT VSMC; however, inhibition of CaMKII significantly blunted the Ang II effect on [Ca 2+ ] i (Figure 2A and 2B). Similar results were obtained with phenylephrine ( Figure 2C ). The LTCC antagonist nifedipine (1 µmol/L) significantly reduced the Ang II-induced increase in [Ca 2+ ] i only in WT but not in TG SM-CaMKIIN cells ( Figure 2B ). These findings show that VSMC Ca 2+ responses to Ang II and phenylephrine are impaired by CaMKII inhibition, possibly as a result of reduced I Ca . We next asked whether Ca 2+ mobilization was affected by CaMKII inhibition in the nominal absence of extracellular Ca 2+ to distinguish CaMKII effects on Ca 2+ entry and intracellular Ca 2+ mobilization. We found identical [Ca 2+ ] i in WT and TG SM-CaMKIIN VSMC after Ang II treatment under Ca 2+ -free conditions ( Figure 2B ), suggesting that CaMKII inhibition reduced [Ca 2+ ] i responses to Ang II and phenylephrine primarily by decreasing Ca 2+ entry. Furthermore, the LTCC opener Bay K8644-stimulated Ca 2+ entry was significantly lower in TG SM-CaMKIIN VSMC compared with WT ( Figure 2D ).
CaMKII Inhibition Decreases SERCA2 Activity and Phospholamban Phosphorylation
Given the reduction in I Ca in VSMC with CaMKII inhibition, we anticipated a corresponding decrease in sarcoplasmic reticulum (SR) Ca 2+ content. To further assess whether the CaMKII inhibition affects the SR Ca 2+ load, we monitored [Ca 2+ ] i after addition of 10 mmol/L caffeine and 10 μmol/L thapsigargin. The increase in [Ca 2+ ] i was rapid and sustained in both WT and TG SM-CaMKIIN VSMC, with a blunted response in TG SM-CaMKIIN VSMC ( Figure 3A and 3B ). The level of SR Figure 3B ). In addition, we calculated the time constant of [Ca 2+ ] i decay after Ang II treatment, which was significantly increased in TG SM-CaMKIIN VSMC (35±3 versus 23±3 s in WT). These data are suggestive of slower SR Ca 2+ uptake.
We next investigated the phosphorylation status of phospholamban (PLB), a CaMKII substrate that is involved in regulating SR Ca 2+ load. PLB associates with and inhibits the SR Ca 2+ -ATPase (SERCA), which is responsible for SR Ca 2+ reuptake. CaMKII-dependent phosphorylation of PLB on Thr17 reverses PLB inhibition of SERCA. PLB Thr17 phosphorylation was 50% lower, and SERCA2 activity was significantly reduced in TG SM-CaMKIIN mesenteric arteries compared with WT ( Figure 3C-3E ). No significant change in SERCA2 protein expression was detected, although SERCA2 mRNA levels were decreased in TG SM-CaMKIIN VSMC ( Figure 3F-3H ). These data suggest that CaMKII controls the SR Ca 2+ uptake in VSMC via phosphorylation of PLB and subsequent SERCA2 activation.
CaMKII Inhibition in VSMC Does Not Alter Agonist-Induced Vasoconstriction
Based on the apparent role of CaMKII in regulating VSMC [Ca 2+ ] i , we hypothesized that CaMKII inhibition would reduce constriction in second-order mesenteric arteries. Surprisingly, we detected comparable levels of steady-state vasoconstriction in WT and TG SM-CaMKIIN mesenteric arteries in response to KCl, phenylephrine, and Ang II ( Figure 4A-4D ). However, the rapid constriction with the LTCC opener Bay K8644 was significantly reduced in mesenteric arteries from TG SM-CaMKIIN mice ( Figure 4E ). Similar levels of rapid and transitional vasoconstriction were observed after application of caffeine ( Figure 4F ). Thus, despite a reduction in agonist-induced [Ca 2+ ] I , the constriction of mesenteric arteries from TG SM-CaMKIIN mice is maintained at normal levels.
Next, we examined the contribution of LTCC activity in vasoconstriction. Pretreatment of mesenteric arteries with 100 nmol/L nifedipine inhibited the agonist-induced constriction in both genotypes, with greater reduction in WT arteries (Figure 4G and 4H) . As the vasoconstriction is almost identical at baseline, this finding supports impaired LTCC function in TG SM-CaMKIIN mice and also suggests that other mechanisms regulating smooth muscle contractile responses, such as Ca 2+ sensitization, are altered in TG SM-CaMKIIN mesenteric arteries.
Pressure-induced constriction, also known as myogenic tone, requires Ca 2+ influx through the LTCC. 29 Similar to agonist-induced vasoconstriction, analysis of myogenic response revealed no difference between genotypes ( Figure 4I ). We also assessed the effect of CaMKII inhibition on structural remodeling. No significant difference in external diameter or wall thickness was noted ( Figure S4 ).
To compare our findings with previously published observations in other vascular beds, we next examined the effect of KN-93 on vasoconstriction of mesenteric arteries. In WT mesenteric arteries, KN-93 significantly impaired vasoconstriction after application of Ang II and phenylephrine, whereas no difference in response to KCl was observed ( Figure S5A-S5C ). In agreement with published evidence, 9 KN-93 decreased constriction of aortic rings when coadministered with KCl but not phenylephrine ( Figure S5D and S5E).
CaMKII Inhibition Increases MLCK Activity
The phosphorylation state of MLC is a major determinant of VSMC contraction and is regulated through the opposing effects of MLCK and MLC phosphatase (MLCP). Despite diminished agonist-induced [Ca 2+ ] i in TG SM-CaMKIIN VSMC, the steady-state vasoconstriction was maintained, suggesting decreased MLCP activity or increased Ca 2+ sensitization under CaMKII inhibition. RhoA/Rho-associated kinase is instrumental in Ca 2+ sensitization of VSMC contraction via Figure 5A ). We confirmed these findings by testing the Ang II-induced mesenteric vasoconstriction in the presence of the Rho kinase inhibitor H-1152 ( Figure 5B ).
Phosphorylation of MLCK at Ser1760 by CaMKII inhibits Ca 2+ -bound calmodulin binding to MLCK and thereby lowers MLCK activity. 5, 6, 30 MLCK phosphorylation under CaMKII inhibition by immunoblot was decreased ( Figure 5C and 5D ). In accordance, the autonomous MLCK activity or the fraction of MLCK that was activated by Ca 2+ -bound calmodulin in vivo was significantly higher in TG SM-CaMKIIN arteries ( Figure 5E ). We also determined the total MLCK activity by adding an excess of Ca 2+ -bound calmodulin. We observed no difference in WT and TG SM-CaMKIIN arteries ( Figure 5E ), suggestive of equivalent MLCK levels. Finally, we assessed phosphorylation of MLC 20, which as the downstream target of MLCK and MLCP is the determinant of VSMC contraction. MLC 20 phosphorylation was not different between genotypes ( Figure 5F and 5G) . These data suggest a model in which CaMKII decreases MLCK activity in vivo. Under CaMKII inhibition, MLCK Ser1760 phosphorylation is decreased, resulting in higher kinase activity despite lower [Ca 2+ ] i . This mechanism counteracts the effects of lower [Ca 2+ ] I and likely contributes to the equivalent vasoconstriction in TG SM-CaMKIIN compared with WT mesenteric arteries.
Discussion
The current dogma is that CaMKII regulates VSMC contraction, despite contradictory findings and limited data. 8, 9 Our study challenges this concept using a novel transgenic model of specific CaMKII inhibition restricted to VSMC. We demonstrate that, despite changes in LTCC activity, [Ca 2+ ] i , and SR Ca 2+ content and uptake, inhibition of CaMKII had no effect on vasoconstriction of mesenteric arteries. One potential reason for the lack of an effect is that inhibition of CaMKII in VSMC significantly impairs LTCC and SERCA function and alters calcium homeostasis through regulation of targets with opposing effects on [Ca 2+ ] i . Our findings also illustrate increased MLCK activity in TG SM-CaMKIIN vessels, providing an additional mechanistic explanation for the similar levels of vasoconstriction. Taken together, this work provides a better understanding of the complex in vivo role of CaMKII in vascular function.
After application of Ang II, [Ca 2+ ] i was significantly reduced in TG SM-CaMKIIN VSMC (Figure 2A and 2B) . The difference was completely abolished after pretreatment with the LTCC blocker nifedipine or under Ca 2+ -free conditions. Thus, the significant decrease in [Ca 2+ ] i in TG SM-CaMKIIN VSMC is driven by reduced Ca 2+ influx from the extracellular space through the LTCC. Furthermore, the SR Ca 2+ content under CaMKII inhibition was significantly reduced ( Figure 3A and 3B), whereas the SR-dependent response to Ang II with nifedipine or under Ca 2+ -free conditions was equivalent ( Figure 2B ). This discrepancy may be reconciled by the slower SR Ca 2+ reuptake because of lower SERCA activity ( Figure 3F ), which is reflected by a lower [Ca 2+ ] i decay constant after Ang II treatment of TG SM-CaMKIIN VSMC. When the Ca 2+ influx from the extracellular space is inhibited, [Ca 2+ ] i is maintained in TG SM-CaMKIIN VSMC after Ang II because of reduced SR Ca 2+ reuptake. Our data also indirectly suggest that the inositol 3 phosphate receptor channel function through which SR Ca 2+ release occurs after Ang II is not impaired in our model. Figures 2D and 4E) . A recent publication in murine sinus nodal cells demonstrated that Bay K8644 does not decrease I Ca under CaMKII inhibition. 31 Consequently, we interpret our findings to demonstrate that lower [Ca 2+ ] i in TG SM-CaMKIIN VSMC reflects decreased SR Ca 2+ mobilization. In contrast to agonist-induced SR Ca 2+ release that is mainly IP 3 receptordependent, 24 the Ca 2+ -induced SR release after Bay K8644 also involves ryanodine receptor opening. CaMKII phosphorylation of ryanodine receptor at Ser 2814 increases its opening probability in cardiac myocytes 32 and skeletal muscle. Our data suggest that CaMKII may also regulate the ryanodine receptor activation state in VSMC and requires further investigation.
Although we detected a significantly reduced SR Ca 2+ load in TG SM-CaMKIIN VSMC compared with WT, the vasoconstriction to caffeine was equal in both genotypes. The absolute SR Ca 2+ release after caffeine was greater than after Ang II (Figures 2A and 3A) . We attribute the similar vasoconstriction to caffeine in WT and TG CaMKIIN mesenteric arteries to saturation of the contractile pathway by relatively high [Ca 2+ ] i . After administration of caffeine, we noted immediate and transient vasoconstriction that only lasted for 10 to 15 s, whereas the [Ca 2+ ] i remained elevated for ≥200 s. This effect may be attributed to the activity of the BK Ca channel. In VSMC, the BK Ca channel is closely coupled to the ryanodine receptor receptor, leading to vasodilation through activation of BK Ca channels. 33 However, the current density of BK Ca channels was not altered in our model (data not shown).
An additional explanation for differential effect of nifedipine on agonist-induced vasoconstriction in WT versus TG SM-CaMKIIN mesenteric vessels is that Ca 2+ sensitization may be increased under CaMKII inhibition. However, we did not find a difference in Rho-associated kinase activity, a major determinant of Ca 2+ sensitization. 34 This finding is in contrast to a recent study that reported inhibition of RhoA activity after silencing of CaMKIIδ in the endothelium. 35 However, we detected significantly increased MLCK activity in TG SM-CaMKIIN arteries, which could contribute to vasoconstriction despite CaMKII inhibition. This result supports the concept that CaMKII provides a negative feedback mechanism for MLC 20 phosphorylation. 36 The effect of CaMKII on smooth muscle function has been widely studied through the use of inhibitors, such as KN-93. [6] [7] [8] [9] KN-93 is a methoxybenzenesulfonamide compound that competes for the calmodulin-binding site of CaMKII. 37 However, KN-93 has known CaMKII-independent effects on the LTCC and voltage-dependent potassium channels. 19, 20, 38 We found that KN-93 inhibited KCl-mediated vasoconstriction in endothelium-denuded aortic ring preparations ( Figure S5C and S5D), in accordance with previous findings. 9 In addition, KN-93 significantly diminished vasoconstriction to Ang II and phenylephrine in mesenteric arteries. In TG SM-CaMKIIN arteries, however, no difference in vasomotor response was seen ( Figure 4A-4D ). We conclude that the reported effects of KN-93 on vascular reactivity are likely caused by its CaMKIIindependent activity. In TG SM-CaMKIIN aortas with intact endothelium, the CaMKII activity was significantly reduced ( Figure S1F ), and a more complete CaMKII inhibition can be expected in situ in the aortic media. This degree of CaMKII inhibition is higher than in a well-established myocardial model in which a similar CaMKII inhibitor peptide was expressed. 23 Thus, we do not believe that the lack of reduction in vasoconstriction is because of insufficient expression or activity of CaMKIIN.
Perspectives
Using a novel transgenic model of specific CaMKII inhibition in VSMC, these data identify CaMKII as a complex regulator of LTCC function, calcium homeostasis, and VSMC contraction. The CaMKII substrates LTCC and PLB in VSMC have an opposing effect on [Ca 2+ ] i . In addition, MLCK activity is increased with CaMKII inhibition, despite lower [Ca 2+ ] i . In contrast to knockout models of LTCC or PLB, 39 CaMKII inhibition does not alter vasoconstriction in resistance blood vessels. These unexpected findings provide more definitive answers to the question whether CaMKII controls vasoconstriction that has been under debate for over a decade. What Is New?
Sources of Funding
• Using a novel, specific transgenic model of Ca 2+ /calmodulindependent kinase II (CaMKII) inhibition in vascular smooth muscle cells, this study demonstrates that CaMKII does not control vasoconstriction in vascular beds relevant for peripheral vascular resistance or blood pressure.
What Is Relevant?
• CaMKII inhibition decreases the L-type Ca 2+ channel current (I Ca ) and cytoplasmic Ca 2+ influx after angiotensin II.
• CaMKII inhibition lowers the total sarcoplasmic reticulum Ca 2+ content caused by diminished sarcoplasmic reticulum Ca 2+ ATPase activity.
• Despite the significant differences in intracellular Ca 2+ , CaMKII inhibition does not alter myogenic tone or vasoconstriction of mesenteric arteries or blood pressure. 
MATERIALS AND METHODS
Reagents
The following antibodies were used in this study: anti-HA tag (Covance), anti-α-smooth muscle actin, anti-β-actin (Santa Cruz Biotechnology), anti-Cavβ 2 (Sigma), anti-Cavβ 3 (Alomone), anti-Cav1.2 (Alomone), anti-HA (Covance), anti-p-PLB Thr17, anti-PLB (Thermo Scientific), anti-SERCA2 (Thermo Scientific), anti-p-MLCK Ser1760 (Invitrogen), anti-MLCK (Abcam), p-MLC20 Thr18/Ser19 and MLC20 (Cell Signaling). The anti-p-Cavβ 2 Thr498 antibody was custom-made against peptide (RQE-pT-FDSETQESRC-amide) by YenZym. The generation of the anti-CaMKII was described previously 1 .
Mice
All experimental procedures were approved by the University of Iowa and the Iowa City VA Health Care System Institutional Animal Care and Use Committee. All procedures were in compliance with the standards for the care and use of laboratory animals of the Institute of Laboratory Animal Resource, National Academy of Science. To study specific CaMKII inhibition in VSMC, we cloned cDNA for the hemagglutinin (HA)-tagged CaMKII inhibitor peptide CaMKIIN (HA-CaMKIIN) into a construct containing the CX-1 promoter and a floxed enhanced GFP sequence 2, 3 . GFP is present ubiquitously in these mice (TG HA-CaMKIIN), but the mice will not express HA-tagged CaMKIIN because of the stop signal immediately downstream of GFP. TG HA-CaMKIIN mice were mated with animals carrying a Cre recombinase gene controlled by the SM22α promoter to generate TG SM-CaMKIIN mice 4 . In mice positive for both the CaMKIIN and Cre transgenes, CaMKIIN is expressed under the control of the CX1 promoter as the floxed GFP cDNA is excised after Cre recombination. All mice were between 10-12 weeks of age.
Histology and immunohistochemistry TG SM-CaMKIIN, TG HA-CaMKIIN and WT littermate arteries were fixed in 4% paraformaldehyde embedded in paraffin. 10 μm sections were collected on Superfrost Plus slides. H&E-staining was performed on some sections. Other sections were preincubated in 5% goat serum for 30 min followed by incubation with primary antibodies against anti-α-smooth muscle actin (1:100) or anti-HA (1:100) overnight at 4°C 5 . Sections were then incubated with Alexa 568-or Alexa 488-conjugated secondary antibodies (Invitrogen). Sections were counterstained with To-Pro-3 (Invitrogen) or embedded in Vectashield containing DAPI (Vector Labs) to visualize nuclei. Images were captured with Zeiss LSM 710m laser scanning microscope.
Quantitative RT-PCR
Total RNA was isolated per manufacturer's recommendation (Qiagen). cDNA was transcribed from 1 μg RNA using Superscript III enzyme (Invitrogen) and random nanomer primers. Message expression was quantified using an iQ Lightcycler (Bio-Rad) with SYBR green dye and normalized to acidic ribosomal phosphoprotein (ARP) mRNA 1 . Real-time PCR was performed using the following primers: HA-CaMKIIN (5'-TGG GAA GAC AAC CTG TAG GG-3' and 5'-CTG TGT CTG GAC GTC CTC CT-3');
Overexpression of Cavβ 2 and Cavβ 3 . HEK cells were transfected at a density of 30% with X-tremeGENE9 DNA Transfection reagent (Roche) according to the manufacturer's recommendations. 1 μg pCMV-HA CaMKIIδ T287D or pCMV-HA empty vector and 3 μg pFLAG-CMV2-Cavβ2a, pcDNA3.1Zeo Cavβ3 or pcDNA3.1 empty vector were used. 48 h after transfection, the cells were harvested and whole cell lysates were prepared for immunoblotting.
Intracellular Ca 2+ measurements
Ang-II stimulated changes in [Ca 2+ ] i in freshly isolated VSMC were assessed by Fura-2 (Molecular Probes) fluorescence ratio imaging using a microscopic digital imaging system (Olympus IX81 Inverted Light Microscope). Cell suspensions were loaded with Fura-2 acetoxymethyl ester (Fura-2 AM, 2 M) as described previously 8 . For the measurements, 500 l of cell solutions were placed on a glass coverslip. The cells were excited alternatively at 340 and 380 nm. Fluorescence signal intensity was acquired at 510 nm. Real-time shifts in Fura-2 ratio fluorescence were recorded before, during and after addition of Ang-II (100 nM) or phenylephrine (10 μM 
SERCA2 activity assay
SERCA ATPase activity was assayed as described previously 10, 11 . The Ca 2+dependent activity was calculated by subtracting the Ca 2+ -independent ATPase activity from the total ATPase activity and then corrected for protein expression revealed by immunoblot.
Vascular reactivity studies
Vascular responses in second-order mesenteric arteries were measured using videomicroscopy using previously published methods 12 . The endothelium was removed and vessel viability determined by measurement of responses to KCl (50 mM). Concentration response curves to Ang-II (10 -9 to 10 -5 M), phenylephrine (10 -8 -10 -6 M), Bay K8644 (1 μM, a selective dihydropyridine Ca 2+ channel agonist) and KCl (25 to 100 mM) were performed. Caffeine (10 mM) was used to test the contribution of SR Ca 2+ to mesenteric vasoconstriction. The role of the LTCC in agonist-induced vasoconstriction was tested by measuring responses to Ang-II and phenylephrine following pretreatment with 100 nM nifedipine. 4) . 48 h after transfection, the cells were harvested and whole cell lysates were prepared for immunoblotting. Lane 7: mouse myocardial whole cell lysate. Phosphorylated Cavβ 2 and Cavβ 3 were detected with a custom-made anti-p-Cavβ 2 Thr498 antibody that was raised against the Cavβ 2 peptide (RQE-pT-FDSETQESRCamide). The overexpression of Cavβ2 and Cavβ3 subunits was verified by immunoblots with β-subunit specific antibodies. HA-tagged CaMKII T287D was detected by blotting with an anti-HA antibody. As predicted, a strong band is present in lane 3 (lysate of HEK cells, transfected with an expression vectors for Cavβ 2 and constitively active CaMKII) . The anti-p-Cavβ 2 Thr498 antibody also detects a band that is likely to represent phospho-Cavβ 3 . This band is only present when constitutively active CaMKII is co-expressed with Cavβ 3 (pcDNA3.1Zeo Cavβ3, lane 6). In a mouse myocardial whole cell lysate, phospho-Cavβ 2 and Cavβ 3 were detected (lane 7). 
